Case number 2024-1094
Teva Pharmaceuticals International GmbH v. Eli Lilly and Company > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Aug 27, 2024 | 43 | The following conflict dates requested by William Barrett Raich for Eli Lilly and Company (see Doc. No. [41]) are not accepted at this time: 12/02/2024, 12/03/2024, 12/04/2024. Please review the Guidance on Oral Argument Scheduling Conflicts for more information. [1028084] [MJL] [Entered: 08/27/2024 03:55 PM] (0) |
| Aug 27, 2024 | 42 | The following conflict dates submitted by William Barrett Raich for Eli Lilly and Company have been accepted by the court: 12/05/2024, 12/06/2024. [1028081] [MJL] [Entered: 08/27/2024 03:54 PM] (0) |
| Aug 26, 2024 | 41 | Notice from Cross-Appellant Eli Lilly and Company regarding conflicts with oral argument. Service: 08/26/2024 by email. [1027743] [24-1094] [William Raich] [Entered: 08/26/2024 04:51 PM] (4) |
| Aug 23, 2024 | 45 | 6 paper copies of Doc. No. [29], [21] received from Cross-Appellant Eli Lilly and Company. [1028262] [VDW] [Entered: 08/28/2024 09:54 AM] (0) |
| Aug 23, 2024 | 44 | 6 paper copies of Doc. No. [35],[22], [16] received from Appellants Teva Pharmaceuticals International GmbH and Teva Pharmaceuticals USA, Inc.. [1028250] [VDW] [Entered: 08/28/2024 09:31 AM] (0) |
| Aug 22, 2024 | 40 | The following conflict dates submitted by Kevin P. Martin for Teva Pharmaceuticals USA, Inc. and Teva Pharmaceuticals International GmbH have been accepted by the court: 11/04/2024, 11/05/2024, 11/06/2024, 11/07/2024, 11/08/2024. [1026912] [MJL] [Entered: 08/22/2024 08:51 AM] (0) |
| Aug 21, 2024 | 39 | Notice from Appellants Teva Pharmaceuticals International GmbH and Teva Pharmaceuticals USA, Inc. regarding conflicts with oral argument. Service: 08/21/2024 by email. [1026876] [24-1094] [Kevin Martin] [Entered: 08/21/2024 05:16 PM] (3) |
| Aug 20, 2024 | 38 | Notice to Advise of Scheduling Conflicts. Arguing counsel must advise of, and show good cause for, any scheduling conflicts during the upcoming court session months listed in the attached notice. The Response to Notice to Advise of Scheduling Conflicts can be found here. The Oral Argument Guide can be found here. [1026291] [GWK] [Entered: 08/20/2024 12:40 PM] (1) |
| Aug 20, 2024 | 37 | Outstanding paper copies of all briefs and appendices must be submitted within five business days from the date of issuance of this notice. See Fed. Cir. R. 25(c)(3)(A). [1026290] [GWK] [Entered: 08/20/2024 12:40 PM] (0) |
| Aug 13, 2024 | 36 | MODIFIED ENTRY: CORRECTED APPENDIX FILED by Appellants Teva Pharmaceuticals International GmbH and Teva Pharmaceuticals USA, Inc.. Service: 08/13/2024 by email. [1024668] --[Edited 08/20/2024 by GWK - Reason: compliance review complete] [Kevin Martin] [Entered: 08/13/2024 03:16 PM] (1363) |
| Aug 13, 2024 | 35 | MODIFIED ENTRY: CORRECTED CONFIDENTIAL APPENDIX FILED by Appellants Teva Pharmaceuticals International GmbH, Teva Pharmaceuticals USA, Inc. and Cross-Appellant Eli Lilly and Company. Service: 08/13/2024 by email. [1024652]--[Edited 08/20/2024 by GWK - Reason: compliance review complete] [Kevin Martin] [Entered: 08/13/2024 03:06 PM] (0) |
| Aug 6, 2024 | 34 | NOTICE OF NON-COMPLIANCE: The submission of Appellants Teva Pharmaceuticals International GmbH and Teva Pharmaceuticals USA, Inc., Appendix, Confidential Appendix [30], [31], is not in compliance with the rules of this court (see attached). Compliant document due on 08/13/2024. Service as of this date by the Clerk of Court. [1023050] [GWK] [Entered: 08/06/2024 10:53 AM] (2) |
| Jul 26, 2024 | 33 | Certificate of Compliance with Fed. Cir. R. 25.1(c)(2) for Appellants Teva Pharmaceuticals International GmbH and Teva Pharmaceuticals USA, Inc.. Service: 07/26/2024 by email. [1020942] [24-1094] [Kevin Martin] [Entered: 07/26/2024 10:36 PM] (2) |
| Jul 26, 2024 | 32 | Certificate of Compliance with Fed. Cir. R. 25.1(c)(2) for Cross-Appellant Eli Lilly and Company. Service: 07/26/2024 by email. [1020940] [24-1094] [J. Jakes] [Entered: 07/26/2024 10:22 PM] (2) |
| Jul 26, 2024 | 31 | APPENDIX FILED by Appellants Teva Pharmaceuticals International GmbH and Teva Pharmaceuticals USA, Inc.. Service: 07/26/2024 by email. [1020939] [24-1094] This document is non-compliant. See Doc No. [34] [Kevin Martin] [Entered: 07/26/2024 10:20 PM] (1359) |
| Jul 26, 2024 | 30 | CONFIDENTIAL APPENDIX FILED by Appellants Teva Pharmaceuticals International GmbH and Teva Pharmaceuticals USA, Inc.. Service: 07/26/2024 by email. [1020938] [24-1094] This document is non-compliant. See Doc No. [34] [Kevin Martin] [Entered: 07/26/2024 09:57 PM] (0) |
| Jul 19, 2024 | 29 | MODIFIED ENTRY: REPLY BRIEF FILED by Cross-Appellant Eli Lilly and Company. Service: 07/19/2024 by email. Unless ordered otherwise, any responsive deadline runs from the date of service of this brief. See Fed. Cir. R. 31. [1019276] --[Edited 07/29/2024 by GWK - Reason: compliance review complete] [J. Jakes] [Entered: 07/19/2024 10:36 PM] (32) |
| Jul 19, 2024 | 28 | Amended Certificate of Interest for Cross-Appellant Eli Lilly and Company. Service: 07/19/2024 by email. [1019275] [24-1094] [J. Jakes] [Entered: 07/19/2024 10:35 PM] (5) |
| Jul 10, 2024 | 27 | ORDER granting motion to extend time to file brief [25] filed by Cross-Appellant Eli Lilly and Company. The reply brief is due 07/19/2024. Service as of this date by the Clerk of Court. [1016713] [LMS] [Entered: 07/10/2024 01:44 PM] (2) |
| Jul 8, 2024 | 26 | Appellants' Statement Regarding Eli Lilly and Company's Motion for Extension of Time for Appellants Teva Pharmaceuticals International GmbH and Teva Pharmaceuticals USA, Inc.. Service: 07/08/2024 by email. [1015929] [24-1094] [Kevin Martin] [Entered: 07/08/2024 10:53 AM] (6) |
| Jul 5, 2024 | 25 | MOTION of Cross-Appellant Eli Lilly and Company to extend the time to 07/19/2024 to file brief. Service: 07/05/2024 by email. [1015842] [24-1094] [William Raich] [Entered: 07/05/2024 07:24 PM] (7) |
| Jun 12, 2024 | 24 | **TEXT ONLY** ORDER granting motion to extend time to file brief [23] filed by Cross-Appellant Eli Lilly and Company. The reply brief is due 07/12/2024. Service as of this date by the Clerk of Court. This order has been issued without an attached document and is official and binding. [1010561] [GWK] [Entered: 06/12/2024 12:57 PM] (0) |
| Jun 11, 2024 | 23 | MOTION of Cross-Appellant Eli Lilly and Company to extend the time to 07/12/2024 to file brief. Service: 06/11/2024 by email. [1010358] [24-1094] [J. Jakes] [Entered: 06/11/2024 04:27 PM] (9) |
| May 29, 2024 | 22 | MODIFIED ENTRY: REPLY BRIEF FILED by Appellants Teva Pharmaceuticals International GmbH and Teva Pharmaceuticals USA, Inc. Service: 05/29/2024 by email. Unless ordered otherwise, any responsive deadline runs from the date of service of this brief. See Fed. Cir. R. 31. [1007189] --[Edited 06/05/2024 by GWK - compliance review complete] [Kevin Martin] [Entered: 05/29/2024 02:09 PM] (65) |
| Apr 19, 2024 | 21 | MODIFIED ENTRY: RESPONSE BRIEF FILED by Cross-Appellant Eli Lilly and Company. Service: 04/19/2024 by email. Unless ordered otherwise, any responsive deadline runs from the date of service of this brief. See Fed. Cir. R. 31. [998979] --[Edited 04/22/2024 by GWK - compliance review complete] [J. Jakes] [Entered: 04/19/2024 07:52 PM] (88) |
| Apr 19, 2024 | 20 | Entry of Appearance for Charles T. Collins-Chase as counsel for Cross-Appellant Eli Lilly and Company. Service: 04/19/2024 by email. [998978] [24-1094] [Charles Collins-Chase] [Entered: 04/19/2024 07:50 PM] (1) |
| Feb 16, 2024 | 19 | **TEXT ONLY** ORDER granting motion to extend time to file brief [18] filed by Cross-Appellant Eli Lilly and Company. The response brief is due 04/19/2024. Service as of this date by the Clerk of Court. This order has been issued without an attached document and is official and binding. [984658] [KMH] [Entered: 02/16/2024 04:05 PM] (0) |
| Feb 14, 2024 | 18 | MOTION of Cross-Appellant Eli Lilly and Company to extend the time to 04/19/2024 to file brief. Service: 02/14/2024 by email. [983832] [24-1094] [Danielle Duszczyszyn] [Entered: 02/14/2024 01:39 PM] (9) |
| Feb 14, 2024 | 17 | Amended Certificate of Interest for Cross-Appellant Eli Lilly and Company. Service: 02/14/2024 by email. [983816] [24-1094] [Danielle Duszczyszyn] [Entered: 02/14/2024 01:07 PM] (4) |
| Feb 2, 2024 | 16 | MODIFIED ENTRY: OPENING BRIEF FILED by Appellants Teva Pharmaceuticals International GmbH and Teva Pharmaceuticals USA, Inc.. Service: 02/02/2024 by email. Unless ordered otherwise, any responsive deadline runs from the date of service of this brief. See Fed. Cir. R. 31. [981334] --[Edited 02/08/2024 by JSP - compliance review complete] [Kevin Martin] [Entered: 02/02/2024 01:46 PM] (357) |
| Feb 2, 2024 | 15 | Entry of Appearance for Elaine Herrmann Blais as counsel for Appellants Teva Pharmaceuticals International GmbH and Teva Pharmaceuticals USA, Inc.. Service: 02/02/2024 by email. [981324] [24-1094] [Elaine Blais] [Entered: 02/02/2024 01:26 PM] (1) |
| Nov 15, 2023 | 14 | Corrected Certificate of Interest for Appellants Teva Pharmaceuticals International GmbH and Teva Pharmaceuticals USA, Inc.. Service: 11/15/2023 by email. [963505] [24-1094] [Kevin Martin] [Entered: 11/15/2023 10:34 AM] (4) |
| Nov 14, 2023 | 13 | Official caption revised to reflect Cross-Appeal 24-1149. (see attached). Service as of this date by the Clerk of Court. [963356] [KMH] [Entered: 11/14/2023 02:26 PM] (2) |
| Nov 14, 2023 | 12 | Note to File: The following cases are consolidated: 24-1094 Lead with 24-1149 Cross-Appeal. The parties must file all documents in the lead appeal only. [963355] [24-1094, 24-1149] [KMH] [Entered: 11/14/2023 02:25 PM] (0) |
| Nov 14, 2023 | 11 | NOTICE OF NON-COMPLIANCE: The submission of Appellants Teva Pharmaceuticals International GmbH and Teva Pharmaceuticals USA, Inc., Certificate of Interest [9], is not in compliance with the rules of this court (see attached). Compliant document due on 11/21/2023. Service as of this date by the Clerk of Court. [963159] [JSP] [Entered: 11/14/2023 08:47 AM] (2) |
| Nov 13, 2023 | 10 | Docketing Statement for the Appellee Eli Lilly and Company. Service: 11/13/2023 by email. [963059] [24-1094] [J. Jakes] [Entered: 11/13/2023 04:43 PM] (3) |
| Nov 13, 2023 | 9 | Certificate of Interest for Appellee Eli Lilly and Company. Service: 11/13/2023 by email. [963055] [24-1094] This document is non-compliant. See Doc No.[11]. [J. Jakes] [Entered: 11/13/2023 04:41 PM] (4) |
| Nov 13, 2023 | 8 | Entry of Appearance for J. Michael Jakes; Charles E. Lipsey; William B. Raich; Danielle A. Duszczyszyn as counsel for Appellee Eli Lilly and Company. Service: 11/13/2023 by email. [963048] [24-1094] [J. Jakes] [Entered: 11/13/2023 04:39 PM] (2) |
| Nov 13, 2023 | 7 | Certificate of Interest for Appellants Teva Pharmaceuticals International GmbH and Teva Pharmaceuticals USA, Inc.. Service: 11/13/2023 by email. [963022] [24-1094] [Kevin Martin] [Entered: 11/13/2023 04:01 PM] (4) |
| Nov 13, 2023 | 6 | Docketing Statement for the Appellants Teva Pharmaceuticals International GmbH and Teva Pharmaceuticals USA, Inc.. Service: 11/13/2023 by email. [963020] [24-1094] [Kevin Martin] [Entered: 11/13/2023 03:58 PM] (2) |
| Nov 9, 2023 | 5 | **TEXT ONLY** ORDER granting motion to extend time to file brief [4] filed by Appellants Teva Pharmaceuticals USA, Inc. and Teva Pharmaceuticals International GmbH. The opening brief is due 02/02/2024. Service as of this date by the Clerk of Court. This order has been issued without an attached document and is official and binding. [962482] [GWK] [Entered: 11/09/2023 10:32 AM] (0) |
| Nov 8, 2023 | 4 | MOTION of Appellants Teva Pharmaceuticals International GmbH and Teva Pharmaceuticals USA, Inc. to extend the time to 02/02/2024 to file brief. Service: 11/08/2023 by email. [962408] [24-1094] [Kevin Martin] [Entered: 11/08/2023 07:37 PM] (9) |
| Nov 7, 2023 | 3 | Transcript Purchase Order Form for the Appellants Teva Pharmaceuticals International GmbH and Teva Pharmaceuticals USA, Inc. indicating that a request is made to the reporter for a transcript. Service: 11/07/2023 by email. [962104] [24-1094] [Kevin Martin] [Entered: 11/07/2023 06:12 PM] (1) |
| Nov 7, 2023 | 2 | Entry of Appearance for Kevin P. Martin; Edwina Clarke; Gabriel Ferrante as counsel for Appellants Teva Pharmaceuticals International GmbH and Teva Pharmaceuticals USA, Inc.. Service: 11/07/2023 by email. [962102] [24-1094] [Kevin Martin] [Entered: 11/07/2023 06:09 PM] (2) |
| Oct 30, 2023 | 1 | Appeal docketed. Received: 10/25/2023. [959956]Entry of Appearance due 11/13/2023. Certificate of Interest is due on 11/13/2023. Docketing Statement due 11/13/2023. Appellant/Petitioner's brief is due 12/29/2023.--[Edited 11/01/2023 by KMH to correct docket statement deadline] [KMH] [Entered: 10/30/2023 11:09 AM] (141) |
